Skip to main content
. Author manuscript; available in PMC: 2022 Jan 31.
Published in final edited form as: Leuk Res. 2019 Sep 28;87:106230. doi: 10.1016/j.leukres.2019.106230

Figure 1: 5-year cumulative incidence of relapse (CIR), cumulative incidence of non-relapse mortality (NRM), relapse free survival (RFS), and overall survival (OS) in patients with (blue line) and without (green line) CMV reactivation.

Figure 1:

(a) CIR by CMV reactivation when examined as a landmark analysis for those without relapse by day 55 post-HCT (b) Cumulative incidence of NRM by CMV reactivation status (c) RFS by CMV reactivation status (d) OS by CMV reactivation status.